Description:
John Theurer Cancer presents the 2023 San Antonio Breast Cancer Review: This program, based on data presented at the San Antonio Breast Cancer Symposium 2023, is designed to provide a review of state of the art information on experimental biology, etiology, prevention, diagnosis & therapy of breast cancer/premalignant breast disease to an audience of academic and private physicians and researchers involved in medical, surgical, GYN and radiation therapy, as well as other appropriate health care professionals
Target Audience:
Physicians, Physician Assistants, Nurse Practitioners, Nurses, Fellows, Residents and Students.
Objectives:
- Who does not get post op RT after NACT clinical T1 disease.
- Breast cancer and future pregnancy
- Inavolisib, an experimental PI3K inhibitor, seems to be more effective than Piqray
- Update of use of solid and liquid biopsies for next gen sequencing
- Triple negative breast cancer- how to decide between Sacituzumab, pembrolizumab or trastuzumab-deruxtecan minimal her 2 neu positive disease
- The role of tucatinib and tmd-1 in the Enherta eta
- How long to give AI’s
- Is there a role of IO with HR+ NACT
John Theurer Cancer Center
92 Second Street
1st Floor Conference Rooms
Hackensack, NJ 07601
February 23, 2024
7:30 AM-3:30 PM